Open Targets Beyond associations: building therapeutic hypotheses with Open Targets [5 minute read] Open Targets directors Ian Dunham and David Hulcoop describe the elements of a full therapeutic hypothesis, and how Open Targets is working to enable the systematic assessment of such hypotheses.
release notes The next-generation Open Targets Platform: rebuilt, redesigned, reimagined [8 minute read] We are delighted to share the new, next-generation Open Targets Platform. It reinvents the best of the old Platform with a redesigned experience, improved usability, based on powerful modern technologies.
Guest Speakers Open Targets hosts Kiran Musunuru: insights into the genetic basis of coronary heart disease [7 minute read] Open Targets recently hosted Prof. Kiran Musunuru, who discussed his work into the genetic basis of coronary heart disease.
experimental science Getting a finer view on genes leading to Alzheimer’s disease risk [4 minute read] In a paper recently published in Nature Genetics, Schwartzentruber and his colleagues found 37 regions associated with Alzheimer’s disease, including 4 regions which hadn’t previously been identified.
Open Targets Platform How we improved our clinical trial curation during the COVID-19 lockdown Learn how we leveraged the wide range of expertise amongst our lab-based experimental research colleagues to make valuable contributions to the Open Targets Platform and our target validation projects.
Open Targets Platform The importance of Autophagy in drug discovery Explore Reactome's new autophagy pathway and how it relates to drug discovery and the Open Targets Platform
Open Targets Platform Introducing ClinGen’s Gene Validity Curations Learn how the Open Targets Platform integrates and scores ClinGen's Gene-Disease Validity curation data to enhance rare disease associations
Open Targets Platform Open Targets Platform 20.09 has been released! We have a new release of the Open Targets Platform - 20.09 - which includes new data from ClinGen, updated Gene2Phenotype data, the removal of duplicated evidence, more clinical trial data, plus regular data updates
coronavirus infectious disease Open Targets releases our COVID-19 Target Prioritisation Tool Open Targets is excited to introduce our COVID-19 Target Prioritisation Tool - http://covid19.opentargets.org/ - an interactive web portal allows users to explore host and viral targets and potential COVID-19 treatments
release notes Open Targets Platform 20.06 has been released! We have a new release of the Open Targets Platform with new disease terms including COVID-19, new chemical probes, updates to Open Targets Genetics evidence and more.
release notes Open Targets Platform 20.04 has been released! We have a new release of the Open Targets Platform with new target safety data, new target tractability modalities, more chemical probes and new associations.
Q&A Prioritising your list of potential drug targets with tractability assessments How tractable is a drug target? In this Open Targets Q&A, we explore the ChEMBL tractability (druggability) pipeline implemented in the Open Targets Platform.
Open Targets Genetics GWAS causal inference in Open Targets Finding GWAS causal inference for target identification and prioritisation using Open Targets Genetics and the Open Targets Platform.
Q&A Special Q&A with Gosia Trynka, Open Targets Experimental Science director We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.
release notes Open Targets Platform 20.02 has been released! We have a new release of the Open Targets Platform with a brand new data source, Open Targets Genetics Portal, more chemical probes and new intOGen data.
Cancer An Open Targets Away Day with The Institute of Cancer Research Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us.
Q&A Getting to know intOGen, a resource for the identification of cancer driver genes Open Targets Q&A on identifying cancer driver genes and their mechanism of action with intOGen.
ontology EFO3: A community-driven ontology to advance clinical discoveries In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.
release notes Open Targets Platform: release 19.11 is out We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.
A-Z From antibody to zinc finger, an A-Z of Open Targets: H As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.
release notes Open Targets Platform: release 19.09 is out We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.
A-Z From antibody to zinc finger, an A-Z of Open Targets: F and G As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.
release notes Open Targets Platform: release 19.06 is out We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.
release notes Open Targets Platform: release 19.04 is out We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.
Q&A Avoiding confusion in disease biology with ontologies Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.
